Literature DB >> 26647102

Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer.

Jian-Qing Huang1, Hong-Ling Liang1, Tian-En Jin1, Zhi Xie2.   

Abstract

Apoptosis-related molecules can be abnormally expressed in cancers and underscore the hallmark of resisting cell death in cancer cells. This study was aimed to observe the expression patterns of apoptosis-related molecules in lung cancer and paired non-cancerous tissues, and to observe if there is a correlation between the expression of these apoptotic molecules and clinicopathologic parameters. Immunohistochemistry (IHC) was performed to analyze the expression level of CASP3, CASP8, CASP9, PARP1, Cleaved CASP3 (C-CASP3), Cleaved PARP1 (C-PARP1), XIAP, BIRC5 (Survivin) and BCL2 in lung cancer and paired non-cancerous tissues. We found that apoptosis-related molecules CASP3, CASP9, BCL2, BIRC5 and PARP1 are abnormally expressed in lung cancer cells and their expression were correlated with histology. BCL2, BIRC5 and PARP1 are expressed at higher levels in SCC than in non-SCC. C-PARP1 expression might be an independent prognostic factor for NSCLC.

Entities:  

Keywords:  Apoptosis; BCL2; PARP1; caspase 3; lung cancer

Mesh:

Substances:

Year:  2015        PMID: 26647102      PMCID: PMC4637667     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  26 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Apoptosis: molecular mechanisms and implications for cancer chemotherapy.

Authors:  H J Guchelaar; A Vermes; I Vermes; C Haanen
Journal:  Pharm World Sci       Date:  1997-06

Review 3.  Molecular mechanisms of caspase regulation during apoptosis.

Authors:  Stefan J Riedl; Yigong Shi
Journal:  Nat Rev Mol Cell Biol       Date:  2004-11       Impact factor: 94.444

4.  Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.

Authors:  Sabina Antonela Antoniu
Journal:  Expert Opin Ther Targets       Date:  2011-01-05       Impact factor: 6.902

5.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

6.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

Review 7.  PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.

Authors:  Kristin K Zorn
Journal:  Oncology (Williston Park)       Date:  2012-02       Impact factor: 2.990

Review 8.  Development and strategies of VEGFR-2/KDR inhibitors.

Authors:  Lingyi Huang; Zhengui Huang; Zhiqiang Bai; Rui Xie; Liping Sun; Kejiang Lin
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

Review 9.  The potential role of mTOR inhibitors in non-small cell lung cancer.

Authors:  Cesare Gridelli; Paolo Maione; Antonio Rossi
Journal:  Oncologist       Date:  2008-02

10.  Lung cancer incidence and survival in chromium exposed individuals with respect to expression of anti-apoptotic protein survivin and tumor suppressor P53 protein.

Authors:  Erika Halasova; M Adamkov; T Matakova; E Kavcova; I Poliacek; A Singliar
Journal:  Eur J Med Res       Date:  2010-11-04       Impact factor: 2.175

View more
  2 in total

1.  Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps.

Authors:  Lubna Danish; Dirke Imig; Frank Allgöwer; Peter Scheurich; Nadine Pollak
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

2.  MicroRNA-326 impairs chemotherapy resistance in non small cell lung cancer by suppressing histone deacetylase SIRT1-mediated HIF1α and elevating VEGFA.

Authors:  Jinying Wei; Guangping Meng; Jing Wu; Ying Wang; Qiang Zhang; Ting Dong; Jin Bao; Chunyan Wang; Jie Zhang
Journal:  Bioengineered       Date:  2022-03       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.